Inari Medical Inc

Inari Medical Inc(NARI)股票分析

$79.970

+0.040 (+0.05%)收盘时

Loading chart…
High
79.990
Open
79.970
VWAP
79.97
Vol
2.36M
Mkt Cap
2.73B
Low
79.960
Amount
188.66M
EV/EBITDA, TTM
243.88

Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss.

估值指标

The current forward P/E ratio for Inari Medical Inc (NARI) is 305.46, compared to its 5-year average forward P/E of 25.78.

Forward P/E

Fair
5Y Average P/E
25.78
Current P/E
305.46
高估
483.03
低估
-431.47

Forward EV/EBITDA

Fair
5Y Average EV/EBITDA
364.10
Current EV/EBITDA
243.88
高估
1708.37
低估
-980.16

Forward P/S

Fair
5Y Average P/S
7.59
Current P/S
6.60
高估
10.51
低估
4.66

NARI FAQ — answered by Alphio AI

Inari Medical, Inc. is a medical device company. The Company’s products primarily consist of ClotTriever and FlowTriever systems, which are catheter-based mechanical thrombectomy systems that are used for the treatment of the venous thromboembolism (VTE) deep vein thrombosis (DVT), and pulmonary embolism (PE). Its InThrill system is used for the removal of emboli and thrombi from the peripheral vasculature. The LimFlow system is indicated for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and are at risk of major amputation. It also offers RevCore thrombectomy catheter, which is a thrombectomy device for venous stent thrombosis, Triever 16 Curve catheter, which is used for venous thrombus removal, and ClotTriever Bold catheter, which is used for DVT and the removal of acute and chronic clots in the peripheral vasculature. Its ClotTriever XL, which is a catheter for efficient clot removal with minimal blood loss. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始